Mechanism of impaired glucose tolerance in patients with neoplasia

B. Jasani, L. J. Donaldson, J. G. Ratcliffe, G. S. Sokhi

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The disappearance rate (k) of i.v. glucose was measured in cachectic and non-cachectic cancer patients and tumour-free controls. The respective k values were found to be 1.06 ± 0.27 (mean ± s.d.), 1.64 ± 0.34 and 1.63 ± 0.23. Of the other parameters measured, only plasma albumin level was found to vary significantly amongst the 3 categories, the mean level being the lowest in cachectic cancer patients. The means of total plasma protein, fasting blood glucose and plasma liver enzyme concentrations were similar in the 3 groups. Glucagon, a potent insulin secretogogue, failed to augment the fasting insulin level in cachectic but did not so in non-cachectic cancer patients. Taken together, the findings suggest that the reduced glucose tolerance in patients with neoplasia is due to impairment of insulin release exhibited predominantly by ill-nourished advanced cancer patients having a moderate to severe degree of hypoalbuminemia.

Original languageEnglish
Pages (from-to)287-292
Number of pages6
JournalBritish Journal of Cancer
Volume38
Issue number2
Publication statusPublished - 1978
Externally publishedYes

Fingerprint

Glucose Intolerance
Neoplasms
Insulin
Fasting
Glucose
Hypoalbuminemia
Glucagon
Serum Albumin
Blood Glucose
Blood Proteins
Liver
Enzymes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Jasani, B., Donaldson, L. J., Ratcliffe, J. G., & Sokhi, G. S. (1978). Mechanism of impaired glucose tolerance in patients with neoplasia. British Journal of Cancer, 38(2), 287-292.

Mechanism of impaired glucose tolerance in patients with neoplasia. / Jasani, B.; Donaldson, L. J.; Ratcliffe, J. G.; Sokhi, G. S.

In: British Journal of Cancer, Vol. 38, No. 2, 1978, p. 287-292.

Research output: Contribution to journalArticle

Jasani, B, Donaldson, LJ, Ratcliffe, JG & Sokhi, GS 1978, 'Mechanism of impaired glucose tolerance in patients with neoplasia', British Journal of Cancer, vol. 38, no. 2, pp. 287-292.
Jasani B, Donaldson LJ, Ratcliffe JG, Sokhi GS. Mechanism of impaired glucose tolerance in patients with neoplasia. British Journal of Cancer. 1978;38(2):287-292.
Jasani, B. ; Donaldson, L. J. ; Ratcliffe, J. G. ; Sokhi, G. S. / Mechanism of impaired glucose tolerance in patients with neoplasia. In: British Journal of Cancer. 1978 ; Vol. 38, No. 2. pp. 287-292.
@article{5cf94c87c7a447c6a0abbf037f609fb5,
title = "Mechanism of impaired glucose tolerance in patients with neoplasia",
abstract = "The disappearance rate (k) of i.v. glucose was measured in cachectic and non-cachectic cancer patients and tumour-free controls. The respective k values were found to be 1.06 ± 0.27 (mean ± s.d.), 1.64 ± 0.34 and 1.63 ± 0.23. Of the other parameters measured, only plasma albumin level was found to vary significantly amongst the 3 categories, the mean level being the lowest in cachectic cancer patients. The means of total plasma protein, fasting blood glucose and plasma liver enzyme concentrations were similar in the 3 groups. Glucagon, a potent insulin secretogogue, failed to augment the fasting insulin level in cachectic but did not so in non-cachectic cancer patients. Taken together, the findings suggest that the reduced glucose tolerance in patients with neoplasia is due to impairment of insulin release exhibited predominantly by ill-nourished advanced cancer patients having a moderate to severe degree of hypoalbuminemia.",
author = "B. Jasani and Donaldson, {L. J.} and Ratcliffe, {J. G.} and Sokhi, {G. S.}",
year = "1978",
language = "English",
volume = "38",
pages = "287--292",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Mechanism of impaired glucose tolerance in patients with neoplasia

AU - Jasani, B.

AU - Donaldson, L. J.

AU - Ratcliffe, J. G.

AU - Sokhi, G. S.

PY - 1978

Y1 - 1978

N2 - The disappearance rate (k) of i.v. glucose was measured in cachectic and non-cachectic cancer patients and tumour-free controls. The respective k values were found to be 1.06 ± 0.27 (mean ± s.d.), 1.64 ± 0.34 and 1.63 ± 0.23. Of the other parameters measured, only plasma albumin level was found to vary significantly amongst the 3 categories, the mean level being the lowest in cachectic cancer patients. The means of total plasma protein, fasting blood glucose and plasma liver enzyme concentrations were similar in the 3 groups. Glucagon, a potent insulin secretogogue, failed to augment the fasting insulin level in cachectic but did not so in non-cachectic cancer patients. Taken together, the findings suggest that the reduced glucose tolerance in patients with neoplasia is due to impairment of insulin release exhibited predominantly by ill-nourished advanced cancer patients having a moderate to severe degree of hypoalbuminemia.

AB - The disappearance rate (k) of i.v. glucose was measured in cachectic and non-cachectic cancer patients and tumour-free controls. The respective k values were found to be 1.06 ± 0.27 (mean ± s.d.), 1.64 ± 0.34 and 1.63 ± 0.23. Of the other parameters measured, only plasma albumin level was found to vary significantly amongst the 3 categories, the mean level being the lowest in cachectic cancer patients. The means of total plasma protein, fasting blood glucose and plasma liver enzyme concentrations were similar in the 3 groups. Glucagon, a potent insulin secretogogue, failed to augment the fasting insulin level in cachectic but did not so in non-cachectic cancer patients. Taken together, the findings suggest that the reduced glucose tolerance in patients with neoplasia is due to impairment of insulin release exhibited predominantly by ill-nourished advanced cancer patients having a moderate to severe degree of hypoalbuminemia.

UR - http://www.scopus.com/inward/record.url?scp=0018091751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018091751&partnerID=8YFLogxK

M3 - Article

VL - 38

SP - 287

EP - 292

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -